November 26, 2021 1:48pm

investors should be thinking more about paring exposure rather than portfolio additions after a big defecate following a two (2) session rally that followed thirteen (13) down sector sessions

Pre-open indication results: 5 HITs, 1` MISS and 1 PUMPED/PROMOTED

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist and pundit; it is that your life and your bank account are largely tied to your questioning of price targets.

The week in review … 

The Dow closed DOWN -905.04 points (-2.53%); the S&P closed DOWN -106.84 points (-2.27%) while the Nasdaq closed DOWN -353.57 points (-2.23%)

 

Henry’omics:

Indexes slumped Friday morning, tracking a sell-off across global markets triggered by new Covid variant fears < B.1.1529 Covid variant, dubbed "Nu”>

It has been called” a constellation of mutations” …

The Cboe Volatility Index, often referred to as the “fear gauge,” rose to 28, its highest level in two months.

While the domestically focused Russell 2000 small-cap index tumbled more than -3%.

Remember, Friday is the day after Thanksgiving, as many traders are enjoying a longer holiday with an early close today; lower liquidity is causing some of this pullback.

 

Note: Moderna (MRNA) shares gained ($56.24 or +20.57%) while Pfizer (PFE) shares added (+3.11 or +6.11%). BioNTech (BNTX), the inventor of the western world's most widely used COVID-19 vaccine, said it expects more data on a worrying new coronavirus variant detected in South Africa within two weeks to help determine whether its shot would have to be reworked (BNTX +$43.24 or +14.19%).

  • Escape variants are those that elude the targeted immune response brought about by vaccination. Should it be necessary, Pfizer and BioNTech would be able to redesign their shot within 6 weeks and ship initial batches within 100 days. <Reuters>

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Friday opened negative at 5 ups/28 downs, 1 flat and 1 acquired, stayed negative at 11 am at 1/31, 2 flats and 1 acquired, ending with a negative close of 3 ups/29 downs, 2 flats and 1 acquired;
  • Thursday was a holiday,
  • Wednesday opened negative at 4 ups/28 downs, 2 flats and 1 acquired, flipped positive at the mid-day at 18/14, 1 flat and 1 acquired, ending with a barely positive close of 23 ups/10 downs, 1 flat and 1 acquired;
  • Tuesday opened negative at 4 ups/28 downs, 2 flats and 1 acquired, stayed negative at the mid-day at 9/24, 1 flat and 1 acquired, ending with a barely positive close of 17 ups/16 downs, 1 flat and 1 acquired;
  • Monday opened negative at 6 ups/27 downs, 1 flat and 1 acquired, stayed negative at the mid-day at 7/26, 1 flat and 1 acquired, ending with a negative close of 6/28 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “a Red versus a Black Friday while a new covid variant surfaces. Risk is dipping beyond comfort levels in a shortened trading day because of the Thanksgiving holiday with U.S. markets closing at 1 p.m. E.T.” … https://www.regmedinvestors.com/articles/12199

 

Pre-open indication results: 5 HITs: Fate Therapeutics (FATE -$1.90), Cellectis SA (CLLS -$0.03), Intellia Therapeutics (NTLA -$2.39), Sage Therapeutics (SAGE -$0.69), CRISPR Therapeutics (CRSP -$2.13)> and 0 MISS <Brainstorm Cell Therapeutics (BCLI +$0.31)> and 1 pumped <Biostage (BSTG +$0.10)>

 

The Biostage (BSTG) Chronicles: Friday closed up +$0.10 with 100 share traded, Thursday markets was closed, Wednesday closed flat with 15 shares traded, Tuesday closed $0.00 with 0 shares traded following Monday closed down again -$0.30 with 1,141 shares traded and last Friday’s -$0.39 to $2.60 with 8,625 shares. Where is the SEC and Nasdaq monitoring?

  • WHY pump the share price with NO clinical trial from a one (1) and 3/4-year-old IND and a negligence rejection of reimbursement in a terminal death suit.
  • What’s there to invest in, the “Sword of Damocles” hanging over the companies non-going operations?

 

Key Metric - volume

Sector volume LOW with 1 of the 3-upside having higher than the 3-month average volume with LOW volume of 2 of 29-downside having higher than the 3-month average volume;

 

There are clear winners and losers

Jumping with share pricing momentum (3 of 3):

  • Biostage (+$0.10),
  • Brainstorm Cell Therapeutics (BCLI +$0.031),
  • Pluristem (PSTI +$0.05),

Hammered in today’s market (10 of 29):

  • ReNeuron (RENE.L -$3.00 after Wednesday’s -$0.50, Tuesday’s -$4.50 and Monday’s+$1.00),
  • BioLife Solutions (BLFS -$2.79 after Wednesday’s -$1.62),
  • Intellia Therapeutics (NTLA -$2.39 after Wednesday’s -$0.49, Tuesday’s -$8.69 and Monday’s -$4.78),
  • Regenxbio (RGNX -$2.25 after Wednesday’s -$0.66, Tuesday’s +$0.15 and Monday’s +$0.21),
  • CRISPR Therapeutics (CRSP -$2.13 after Wednesday’s +$0.84 after Tuesday’s -$0.51),
  • Fate Therapeutics (FATE -$1.90 after Wednesday’s +$2.23, Tuesday’s -$0.26 and Monday’s -$3.52),
  • Vericel (VCEL -$1.88 after Wednesday’s -$0.41),
  • Ultragenyx (RARE -$1.09 after Wednesday’s +$0.58, Tuesday’s -$0.62 and Monday’s -$01.70),
  • Global Blood Therapeutics (GBT -$1.04),
  • Chinook Therapeutics (KDNY -$1.04 after Wednesday’s -$0.41 and Tuesday’s +$1.13),

Closing Flat:

  • 2 – Bellicum Pharmaceuticals (BLCM), Caladrius Biosciences (CLBS) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed up +0.98% and XBI closed down -2.72%
  • Thursday, markets were closed
  • Wednesday, the IBB closed UP +0.25% and XBI closed up +0.56%
  • Tuesday, the IBB closed down -0.44% and XBI closed up +0.08%
  • Monday, the IBB closed down -0.57% and XBI closed down -2.17%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +10.04 points or +54.04% at 28.62
  • Thursday was a holiday
  • Wednesday was down -0.80 points or -4.13% at 14.58
  • Tuesday was up +0.21 points or +1.10% at 19.38
  • Monday was up +1.26 points or +7.04% at 19.17

 

November, the second month of Q4/21:

Friday closed negative with 3 incliners, 29 decliners, 2 flats and 1 acquired

Thursday was Thanksgiving holiday

Wednesday closed positive with 23 incliners, 10 decliners, 1 flat and 1 acquired

Tuesday closed positive with 17 incliners, 16 decliners, 1 flat and 1 acquired

Monday (11/22) closed negative with 6 incliners, 28 decliners and 1 acquired

 

 

The BOTTOM LINE: Markets were closed on Thursday for Thanksgiving; sector stocks came-off slight gains on Wednesday and Tuesday that staunched the previous thirteen (13) sessions’ losses as “NU” covid variations scare markets.

Sector equities are not easy to buy in this environment, especially after today’s BIG “dump”.

Should investors be tempted to buy or add to new or current holdings that COULD rebound from the 50-day or even 21-day lines. It's a high-risk, high-reward strategy. The two (2) session rally after thirteen (13) down session is STILL questionable as I have NOT seen any news to qualify an upside trend.

I still am dubious as today is a sell stop-washout scenario.

It comes down to your investing style. How aggressive are you, comfortable with current holdings, and how quickly will you exit losing trades?

We are about to enter into TAX SELLING for year’s end!

In any case, I wouldn’t ramp up your exposure at the current levels.

There's also nothing wrong with standing pat after reducing exposure earlier in the month.

Investors don't always have to be trading.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

The week in review …

Monday

RegMed Investors’ (RMi) pre-open: if going to sell, wait for a strengthening … https://www.regmedinvestors.com/articles/12193

RegMed Investors’ (RMi) closing bell: Friday’s diving is more than a watersport … https://www.regmedinvestors.com/articles/12192

 

Tuesday

RegMed Investors’ (RMi) pre-open: weighing the risks of low volume and a shortened week while catalysts aren’t apparent … https://www.regmedinvestors.com/articles/12195

RegMed Investors’ (RMi) closing bell: the afternoon sprung the cell and gene therapy sector to life … https://www.regmedinvestors.com/articles/12196

 

Wednesday

RegMed Investors’ (RMi) pre-open: Happy Thanksgiving, got to go … https://www.regmedinvestors.com/articles/12197

RegMed Investors’ (RMi) closing bell: the week is almost over – celebrate Thanksgiving, forget markets; dig into the stuffing … https://www.regmedinvestors.com/articles/12198

 

Thursday – a market holiday

Happy Thanksgiving ... giving thanks and be SAFE! … https://www.regmedinvestors.com/articles/5855

 

Friday

RegMed Investors’ (RMi) pre-open: a Red versus a Black Friday while a new covid variant surfaces … https://www.regmedinvestors.com/articles/12199

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.